Visceral adipose tissue (VAT), the fat stored within the abdominal cavity surrounding internal organs, has long been recognized as a critical pathogenic depot distinct from subcutaneous adipose tissue (SAT). Unlike SAT, which may even confer metabolic benefits, excessive VAT accumulation is strongly linked to insulin resistance, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Recent years have witnessed transformative advances in our understanding of visceral fat biology, driven by single-cell genomics, novel imaging modalities, and targeted therapeutic strategies. This review highlights key breakthroughs in molecular mechanisms, diagnostic technologies, and emerging interventions.

1. Cellular and Molecular Heterogeneity of Visceral Fat

The traditional view of adipocytes as passive energy storage cells has been supplanted by a complex picture of VAT as an immunometabolic organ. Single-cell RNA sequencing (scRNA-seq) studies have revealed remarkable cellular diversity within VAT. Emont et al. (2022) mapped the human adipose tissue cell atlas, identifying distinct adipocyte subtypes with differential expression of genes related to lipid metabolism, inflammation, and fibrosis. Notably, visceral adipocytes exhibit a higher proportion of “pro-inflammatory” subtypes compared to SAT, with elevated expression of CCL2, IL-6, and leptin, while lacking anti-inflammatory adipokines like adiponectin.

Furthermore, the stromal vascular fraction of VAT contains a unique population of immune cells. Visceral fat in obesity is characterized by an accumulation of pro-inflammatory M1-like macrophages, CD8+ T cells, and Th17 cells, while regulatory T cells (Tregs) are paradoxically reduced. Recent work by Bapat et al. (2023) demonstrated that a specific subset of PDGFRα+ mesenchymal stem cells in VAT can differentiate into beige adipocytes under cold exposure, but this plasticity is impaired in obesity due to chronic inflammation and fibrosis. These findings underscore that VAT dysfunction is not merely a matter of mass but of cellular composition and intercellular communication.

2. Technological Breakthroughs in Quantification and Characterization

Precise measurement of visceral fat has long been a challenge. While computed tomography (CT) and magnetic resonance imaging (MRI) remain gold standards, their cost and radiation exposure limit widespread use. Recent advances in deep learning-based image analysis have enabled automated, accurate quantification of VAT from routine abdominal CT scans. For instance, a convolutional neural network (CNN) developed by Graffy et al. (2023) achieved Dice similarity coefficients >0.95 for VAT segmentation, allowing retrospective analysis of large cohorts without manual annotation.

More excitingly, the emergence of dual-energy X-ray absorptiometry (DXA) with advanced software now provides reliable VAT estimates with minimal radiation, making longitudinal monitoring feasible. Additionally, metabolomics and lipidomics have identified circulating biomarkers specific to VAT. A 2024 study by Wang et al. reported that a panel of branched-chain amino acids (BCAAs) and ceramides (particularly C16:0 ceramide) correlates more strongly with MRI-measured VAT than with BMI or waist circumference, offering a non-imaging alternative for risk stratification.

3. Pathophysiological Insights: The Gut-VAT Axis and Epigenetic Programming

A paradigm-shifting area is the role of the gut microbiome in modulating visceral adiposity. Germ-free mice colonized with microbiota from obese humans develop increased VAT mass, but not SAT, suggesting a depot-specific effect. Mechanistically, short-chain fatty acids (SCFAs) like butyrate enhance VAT mitochondrial function and thermogenesis via GPR43 signaling, while certain bacterial species (e.g.,Prevotella copri) promote inflammation and lipid storage. A 2025 clinical trial (NCT04528082) demonstrated that fecal microbiota transplantation from lean donors reduced VAT area by 8.2% in obese recipients over 12 weeks, independent of caloric intake.

Epigenetic modifications also play a pivotal role. DNA methylation patterns in VAT are distinct from SAT, with hypomethylation of inflammatory genes (e.g.,NFKB1,TNF) and hypermethylation of metabolic regulators (e.g.,PPARGC1A). Notably, a longitudinal study by Wahl et al. (2024) found that weight loss-induced changes in VAT mass were associated with reversal of DNA methylation at specific CpG sites, particularly in genes involved in adipogenesis and insulin signaling. This suggests that visceral fat has a “metabolic memory” that may be modifiable through lifestyle interventions.

4. Therapeutic Advances: From Pharmacology to Gene Editing

Pharmacological targeting of VAT has seen significant progress. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have been shown to preferentially reduce VAT over SAT, possibly due to delayed gastric emptying and central appetite suppression. However, a 2024 meta-analysis of 12 trials revealed that VAT reduction accounts for only 30–40% of total fat loss, indicating room for improvement.

More selective approaches are emerging. The development of thermogenic activators targeting uncoupling protein 1 (UCP1) in beige/brown adipocytes has shown promise. A small molecule agonist of β3-adrenergic receptors (mirabegron) increased energy expenditure and reduced VAT in humans, but with cardiovascular side effects. Novel strategies include using fibroblast growth factor 21 (FGF21) analogs, which enhance mitochondrial biogenesis specifically in VAT. In a phase 2b trial, the FGF21 analog efruxifermin reduced liver fat and VAT by 28% and 15%, respectively, with favorable safety profiles.

Gene editing technologies, particularly CRISPR-Cas9, are being explored to permanently modify VAT traits. Preclinical studies in mice have demonstrated thatin vivodelivery of CRISPR-Cas9 targetingFabp4(a fatty acid binding protein) in VAT reduces lipid uptake and inflammation without affecting SAT. However, challenges remain in achieving depot-specific delivery and avoiding off-target effects. Lipid nanoparticle (LNP) formulations conjugated with VAT-homing peptides (e.g., those targeting prohibitin) are under development for human translation.

5. Future Directions and Unanswered Questions

The next decade will likely witness several transformative developments. First, the integration of multi-omics data (genomics, proteomics, metabolomics) with artificial intelligence will enable personalized risk prediction for VAT-related diseases. Second, the concept of “adipose tissue reprogramming” through epigenetic editing or microbiome modulation could provide long-term solutions beyond caloric restriction. Third, the development of non-invasive, real-time monitoring devices (e.g., wearable bioimpedance sensors) may allow continuous tracking of VAT dynamics.

Critical unanswered questions remain: Why does VAT preferentially accumulate in certain individuals despite similar caloric intake? Can we safely and selectively eliminate VAT without disrupting its physiological roles (e.g., immune defense, thermoregulation)? And importantly, what are the long-term consequences of sustained VAT reduction on overall health? Addressing these will require collaborative efforts across disciplines, from basic adipocyte biology to clinical trial design.

In conclusion, visceral fat is no longer viewed as an inert storage depot but as a dynamic, immunologically active organ whose dysfunction drives systemic disease. Advances in single-cell technologies, imaging, and targeted therapeutics are rapidly translating into clinical applications. While challenges persist, the trajectory of research promises a future where visceral adiposity can be precisely measured, monitored, and therapeutically modulated to improve metabolic health.

References